Category

Projects

ITU – XPRIZE Inaugural AI for Good Summit Takes Place in Geneva

By | Projects | No Comments

ITU – XPRIZE Inaugural AI for Good Summit Takes Place in Geneva
Invited Speaker Barry Ressler, Chairman & CEO of ISMC, discusses the use and challenges of Artificial Intelligence for Citizen Health and Medical Ethics

Geneva, Switzerland, (June 7-9, 2017) ISMC Chairman and CEO Barry Ressler took part in the United Nations International Telecommunication Union (ITU) – XPRIZE inaugural Summit on Artificial Intelligence for Good as an invited speaker. The groundbreaking event brought together policymakers, industry leaders, financial institutions, academia and civil society from both developed and developing countries, as well as United Nations agencies, to discuss the role Artificial Intelligence (AI) can play in solving humanity’s biggest challenges. Special attention was given to how AI can be used to help achieve the United Nations’ Sustainable Development Goals.

The three-day summit, whose opening speakers included Houlin Zhao, Secretary-General of the ITU and Marcus Shingles, CEO of the XPRIZE Foundation, provided an excellent forum for debate on the importance and future of AI solutions in addressing global issues like hunger, poverty, health and the environment. Mr Ressler highlighted some significant AI applications under development by ISMC, focused on education, space medicine, and food/agriculture. He focused on diagnosing the speciation and state of viral, bacterial, fungi, spore and amoeba pathogens at the early stage of an outbreak based on patented algorithms and empirically proven dynamic modeling and simulation to be machine learned by an AI platform. This is not to treat patients but to mitigate the source of infection. The objective is to offset a remote, out of control epidemic/pandemic. The technology and systems that we are developing for Low earth Orbit conditions and eventually interplanetary colonization is about as remote as you can get compared to isolated remote locations on earth. Mr. Ressler further commented on the critical need to address antimicrobial resistance, a priority area shared by the World Health Organization (WHO).

ISMC was also represented at the meeting by COO Steve Diamond, and Fabrizio Gramuglio, CEO of their affiliate company Forever Identity and John Vickers, Managing Director of their partner project company Blue Abyss, an enterprise aiming to build a premier aquatic and space extreme environment research, development and training facility in the UK. Mr Ressler was joined on the Artificial Intelligence for Citizen Health and Medical Ethics panel by Abha Saxena, Coordinator of Global Health Ethics for the World Health Organization (WHO), Jay Komarneni, Founder & Chair of the Human Diagnosis Project, and Christiane Woopen, Professor of Ethics and Theory of Medicine, University of Cologne, in what was an excellent opportunity to build and strengthen networks with respected innovators in the field of AI.

The panel was moderated by Mohamed Alkady, the president of Hart, a medical technology company that’s improving the ways in which people inside and outside of the industry access and engage with health data.

About ISMC, Inc.
ISMC is committed to advancing the state-of-the-art in the innovative field of space medicine and to collaborate with leading space communities and organizations in the exciting area of human space exploration. It further aims to connect space exploration and humanity by pioneering space medicine technologies and applications. This commitment will position ISMC in support of future international human spaceflight missions and the emerging commercial space tourism industry.

Contact:
International Space Medicine Consortium Inc.
Phone: USA +1-202-429-8439
info@spacemedicineconsortium.com

THE ISMC LED PROJECT FOR SPACE (LEO and Interplanetary) MISSIONS

By | Projects | No Comments

In January 2015, the ISMC science team participated in research studies concerning viral and bacterial contamination of the environment and focused on health, food/beverage, agriculture and aquaculture including the application of transgenic science. The various technologies and protocols available at that time were large, heavy and required high kW of input power.  The requisite cooling systems and materials to protect the operators (radiation, HV, optical wavelengths) added to the size and weight problem.

One of ISMC’s priorities was to develop diagnostic and therapeutic systems with protocols that could operate in microgravity orbiting environs (ISS) and LEO operating stations (water mining, refueling).  We also knew that interplanetary colonization would require compact, lightweight, utility power and maintenance in a robust package to withstand the radiation and hyper/micro-G operating conditions.  We investigated the current state of the art in X-Ray, Gamma Ray, E-O, and UV, including  LP, MP, mercury, amalgam and dielectric barrier discharge (DBD) germicidal light sources, but did not find them appropriate for space applications

In April, 2015, ISMC initiated an internally funded research program, the ISMC LED PROJECT for space (LEO and Interplanetary). We compared existing systems to the current state of the art of high spectral intensity SMD LED’s at discreet narrow germicidal lambda.  ISMC, with support from STAR Associates Inc, initially created various array configurations of multiple LED elements to map and determine the optimum geometric distribution to deliver germicidal uniformity.  We then exposed the LED array of germicidal light to a range of cross sectional areas and measured the intensity roll-off with respect to distance from the LED array light source. STAR conducted these initial experiments using LEDs from 3 global manufacturers and determined that only one had the capability to meet the spectral intensity, repeatability and environmental conditions for space applications.

Once the spectral intensity data profiles had been established, the next eight months were dedicated to testing the LED arrays to identify dose response for specific panels of bacterial and viral organisms that have been identified as primary microbes in space.

The first objective was to establish the DNA/nucleic acid metabolic recovery and profile the repair cycle using the LED arrays.  These test and measurement data sets were conducted using 6 germicidal wavelengths with increasing spectral intensity steps to determine “D” value comparatives to published data using other established methods.

Importantly, we were able to achieve comparable data to current technology but at dramatic reductions in size and weight. We unexpectedly observed new advanced intercept methods of repair protocols that were not readily achievable using conventional technology.

We are well aware that our designated target microbes will be mutated during transit to LEO and that our 1-G findings will need to be retested for verification on the mutated state in LEO.  In consideration of unmanned orbiting experiments, ISMC and its affiliated company, Forever Identity, have been evaluating the use of AI, HCI, machine learning and expert systems studies on our process.

We are seeking project partners and financing to initiate the next phase of our project to compare our 1-G data under micro-G conditions.  Since the mutated changes will be the norm that will dominate microbes in space for humanity, the ISMC  platform will  be able to provide the rugged reliability, reproducibility, reduced size and light weight needed in space.

Osteoclast’s Impact in Causing Osteoporosis in Microgravity with and without Radiation Effect

By | Projects | No Comments

The causes of osteoporosis in microgravity may be manifold. Most of the research has been dedicated to studying bone weight loading, muscle atrophy, osteoblastic biocellular changes and paratharmone effects. These studies are focused on bone formation while little research has been performed on bone resorption. ISMC has focused on the the resorption mechanism of the osteoclast at 1-G, hyper-G during transport and in micro-gravity.

We have applied mathematical modeling to confirm our understanding of the effects of osteoblast/osteoclast changes on the balance of bone formation. Multivariable analysis helps understand how the molecular biological changes of the osteoclast in micro-gravity, with and without radiation, effects osteoporosis.

Space radiation ((gamma, proton, carbon and ion) increases the bone loss risks of microgravity exposure. This leads to premature onset of osteoporosis, fractures, arterial calcification, mineral leaching and decreased bone quality. Literature has shown that serum markers for bone formation and resorption from the ion radiation exposed rats have indicated that the bone loss is caused by increased osteoclastic bone resorption. During space flight, osteoclast activation through skeletal unloading has also been noted to cause bone loss. ISMC plans to add studies of the mechanisms associated with increased osteoclastogenesis under exposure to space radiation. We understand that osteoporosis after radiation therapy is also a problem.

This will enable not only the development of suitable anti-resorptive countermeasures requiring minimal intervention, but also in ascertaining optimal dosage for therapy. Our modeling with our University partners will help us predict the threshold RANKL concentration likely to induce increased osteoclast genesis in microgravity.

Our studies and research interest of the osteoclast can lead to new pharmaceuticals that can interfere with bone resorption in MicroG; however, the findings can also be used to prevent osteoporosis at 1G.

ISMC welcomes collaboration with experts, universities, government agencies and corporations

Osteoporosis after radiation therapy is a problem.

Interactive Behavioral Health Psychologist Persona

By | Projects | No Comments

International Space Medicine Consortium Inc with support from its affiliate company, Forever Identity (www.foreverIdentity.it) in Milan/Genoa Italy, have applied our patented (issued and Pending) Dialog stimuli recognition management, emotion/empathy platform and ethical/morality AI subset to space medicine applications.  This scientific/engineering research and application specific product development is further supported by our internal research and development AI, HCI /Voice Recognition, Expert Systems team, consultants and subcontractors. We seek and engage AI partners for NLG and machine learning.

ISMC has created a model for an Interactive Behavioral Health Psychologist for space mission long term group isolations. In association with leading psychologists who focus on emotional intelligence and analysis of facial expression, ISMC’s Senior Advisor on Human Persona Robotics HCI has created an emotional, empathetic Persona that can interact with a person through biosensors and expert psychological behavioral health knowledge. The interaction is compared to an individual baseline emotional pattern to changes measured during the present interaction. Facial expression, biosensors, body movements and voice modulations will be integrated into the Persona through its Hierarchy Matrix that prioritizes input importance. The Persona has the ability to learn and interact with evolving emotional and behavior health changes.

The evolution of this Behavioral Health Psychologist Persona can be used on an everyday basis on earth. Initially it can be used for people or groups in isolated positions. Eventually the Persona through AI will fill the void occurring due to the decreasing number of psychiatrists and behavioral health workers. Once an early detection of a behavioral health problem is identified, modalities of treatment, such as cognitive therapy, can be suggested.

ISMC welcomes experts, universities, government and corporate partners who can help the evolution of the Behavioral Health Psychologist Persona and who can assist our team to create Cognitive Treatment Intelligence for the Persona to suggest treatments to counter the emotional changes realized.

The effects of e‐peptide on breast cancer Tumor cells and mesenchymal stem cells in microgravity

By | Projects | No Comments

ISMC, and its affiliate company, E-P Therapeutics Inc, have been studying the application of our discovery and patent protected Human E-Peptide (designated as hEb) in microgravity as a part of our interest in the Humans in Space and Microbes in Space programs.  The hEb has been shown to down-regulate malignant cellular growth and kill many different malignant cell lines by apoptosis.  Cancer cells that have been studied are:

  • Breast cancer cells (MDA-MB-231 and ZR-75-1)
  • Colon cancer cells (HT29)
  • Hepatoma cells (HepG2)
  • Leukemia cells
  • Neuroblastoma cells (SK-N-F1)
  • Ovarian cancer cells (SKOV and OVCAR)
  • Protease cancer cells (PC3)
  • Small lung cancer cells (NCI-H526F)

Our hEb represents the cleavage of the terminal carboxy end of a pro-IGF-1 molecule. When cleavage occurs, IGF-1 is released and hEb is found as independent molecules. It is water soluble and heat-resistant, and it also has an anti-angiogenesis effect by inhibiting endothelial cell growth. There is evidence that hEb has an inhibitory effect on malignant stem cells.

Studies demonstrate that mesenchymal stem cells (MSC) enhance neoplastic growth while others demonstrate an anti-tumorigenic quality. It is known that MSC have the ability to migrate to tumor sites and react with tumors. MSC can also respond to inflammation around the tumor and deliver cytokines, necrosis factor and interleukin-6, around the tumor environment. The interaction of hEb and mesenchymal stem cells should potentiate tumor necrosis.

 

Our ISMC research has considered the hyper-G and micro-G challenges associated with transport to the ISS. We understand that the proliferation of malignant MDA-MB231 breast cancer cells in microgravity to be greater than the same tumor cells grown at 1G.  Our aim is to test the ability of hEb to respond to faster growing tumor cells and demonstrate its ability to function in a very aggressive environment. MDA-MB231 breast cancer cells in micro-gravity have cell survival up-regulated. This will challenge hEb’s ability to kill cancer cells by apoptosis. Mesenchymal Stem Cells will also be tested against the breast cancer cells to evaluate its effect on tumor growth. The effect of E-Peptide on MSC will also be observed. If successful, this study would demonstrate the potential for hEb to be developed as a novel chemotherapeutic agent. It will also show the effects of Mesenchymal Stem Cells on tumor growth and its use in cancer treatment.

 

ISMC welcomes inquiries from research organizations, universities, government and corporate partners to accelerate our project and to participate in the health and well-being of humanity in the exploration of space and interplanetary colonization.